NCT03183024 is a Phase 4 clinical trial of benralizumab in Chronic Idiopathic Urticaria, sponsored by Jonathan A. Bernstein, MD.

Who is sponsoring NCT03183024?

NCT03183024 is sponsored by Jonathan A. Bernstein, MD.

What drugs are being tested in NCT03183024?

Interventions in NCT03183024: benralizumab, placebo.

What condition does NCT03183024 study?

NCT03183024 studies Chronic Idiopathic Urticaria.

Is NCT03183024 still recruiting?

NCT03183024 is currently completed. Last updated 10 July 2019.

Last reviewed 2019-07-10 · How we verify

NCT03183024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

Completed Phase 4 Last updated 10 July 2019

What this trial tests

Phase 4 trial testing benralizumab in Chronic Idiopathic Urticaria in 12 participants. Completed in 6 November 2018.

Timeline

12 September 2017

Primary endpoint
6 November 2018

6 November 2018

Quick facts

Lead sponsor	Jonathan A. Bernstein, MD
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	12
Start date	12 September 2017
Primary completion	6 November 2018
Estimated completion	6 November 2018
Sites	1 location across United States

Drugs / interventions tested

benralizumab (BENRALIZUMAB) — full drug profile →
placebo

Conditions studied

Chronic Idiopathic Urticaria — all drugs for Chronic Idiopathic Urticaria →

Sponsor

Jonathan A. Bernstein, MD — full company profile →

Who can join

Adults 19 to 70, any sex, with Chronic Idiopathic Urticaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study to determine the efficacy of benralizumab when compared to placebo in patients with chronic hives that do not respond to antihistamine treatment

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.
Jacobsen EA, Jackson DJ, Heffler E, Mathur SK, et al · · 2021 · cited 95× · PMID 33646859 · DOI 10.1146/annurev-immunol-093019-125918
Current and emerging treatments for chronic spontaneous urticaria.
Johal KJ, Saini SS. · · 2020 · cited 26× · PMID 31494233 · DOI 10.1016/j.anai.2019.08.465
Emerging Therapies in Chronic Spontaneous Urticaria.
Min TK, Saini SS. · · 2019 · cited 21× · PMID 31172716 · DOI 10.4168/aair.2019.11.4.470
Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success.
Armstrong AW, Soong W, Bernstein JA. · · 2023 · cited 17× · PMID 37354293 · DOI 10.1007/s13555-023-00955-7
Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review.
Wong MM, Keith PK. · · 2020 · cited 13× · PMID 32944029 · DOI 10.1186/s13223-020-00461-x
The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review.
Gomes M, Mendes A, Ferreira F, Branco J, et al · · 2023 · cited 3× · PMID 37138643 · DOI 10.1155/2023/8832242

Verify or expand the search:

Other trials of benralizumab

Trials testing the same drug.

NCT07214753 — A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy · recruiting
NCT06862206 — This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patient · recruiting
NCT06750289 — Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontroll · Phase 3 · recruiting
NCT02130882 — Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome · Phase 2, PHASE3 · unknown

Other Jonathan A. Bernstein, MD trials

Trials by the same sponsor.

NCT04358224 — The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183024 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonathan A. Bernstein, MD
Last refreshed: 10 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing